RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación
Artículo científico (JournalArticle)
Identification of atrial fibrillation drivers by means of concentric ring electrodes
[EN] Background and objective: The prevalence of atrial fibrillation (AF) has tripled in the last 50 years due to population aging. High-frequency (DFdriver) activated atrial regions lead the activation of the rest of the atria, disrupting the propagation wavefront. Fourier based spectral analysis of body surface potential maps have been
proposed for DFdriver identification, although these approaches present serious drawbacks due to their limited
spectral resolution for short AF epochs and the blurring effect of the volume conductor. Laplacian signals (BCECG) from bipolar concentric ring electrodes (CRE) have been shown to outperform the spatial resolution
achieved with conventional unipolar recordings. Our aimed was to determine the best DFdriver estimator in
endocardial electrograms and to assess the BC-ECG capacity of CRE to quantify AF activity non-invasively.
Methods: 31 AF episodes were simulated using realistic tridimensional models of the atria electrical activity and
torso. Periodogram and autoregressive (AR) spectral estimators were computed and the percentile (P90th, P95th
and P98th) to impose on the dominant frequencies (DFs) across whole atria to define the best DFdriver estimator
evaluated. The identification of DFdriver on DFs from BC-ECG and unipolar surface signals with conventional
disc electrodes was compared.
Results: The best DFdriver estimator was P95th and AR order 100. BC-ECG signals allowed better detection of AF
activity than unipolar signals, with a significantly greater percentage of electrode locations in which DFdriver
was identified (p-value 0.0095).
Conclusions: The use of BC-ECG signals for body surface Laplacian potential mapping with CRE could be helpful
for better AF diagnosis, prognosis and ablation procedures than those with conventional disk electrodes., This work was supported by the Spanish Ministry of Economy and Competitiveness (PID2020-114291RB-I00) and the Instituto de Salud Carlos III, the European Regional Development Fund (MCIU/AEI/FEDER, UE RTI2018-094449-A-I00-AR, PI17/01106) , EIT Health (Activity code 19600, EIT Health is supported by EIT, a body of the European Union) and the Generalitat Valenciana (AICO/2021/318, AICO/2021/126 and AICO/2019/220) .
Proyecto:
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-114291RB-I00
,
European Regional Development Fund / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 EITHealth 19600 AFFINE
,
Agencia Estatal de Investigación RTI2018-094449-A-I00
,
Generalitat Valenciana AICO/2019/220
,
Generalitat Valenciana AICO/2021/318
,
Generalitat Valenciana AICO/2021/126
,
Instituto de Salud Carlos III PI17/01106